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Abstract
Much emphasis has been placed on the identification, functional characterization, and therapeutic potential of somatic
variants in tumor genomes. However, the majority of somatic variants lie outside coding regions and their role in cancer
progression remains to be determined. In order to establish a system to test the functional importance of non-coding
somatic variants in cancer, we created a low-passage cell culture of a metastatic melanoma tumor sample. As a foundation
for interpreting functional assays, we performed whole-genome sequencing and analysis of this cell culture, the metastatic
tumor from which it was derived, and the patient-matched normal genomes. When comparing somatic mutations identified
in the cell culture and tissue genomes, we observe concordance at the majority of single nucleotide variants, whereas copy
number changes are more variable. To understand the functional impact of non-coding somatic variation, we leveraged
functional data generated by the ENCODE Project Consortium. We analyzed regulatory regions derived from multiple
different cell types and found that melanocyte-specific regions are among the most depleted for somatic mutation
accumulation. Significant depletion in other cell types suggests the metastatic melanoma cells de-differentiated to a more
basal regulatory state. Experimental identification of genome-wide regulatory sites in two different melanoma samples
supports this observation. Together, these results show that mutation accumulation in metastatic melanoma is nonrandom
across the genome and that a de-differentiated regulatory architecture is common among different samples. Our findings
enable identification of the underlying genetic components of melanoma and define the differences between a tissue-
derived tumor sample and the cell culture created from it. Such information helps establish a broader mechanistic
understanding of the linkage between non-coding genomic variations and the cellular evolution of cancer.
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Introduction
Sporadic cancer is mainly caused by the progressive accumula-
tion of genomic mutations. Therefore, a mechanistic understanding
of cancer requires a comprehensive catalog of all somatic variants in
a tumor genome. Although the majority of somatic variants occur in
non-coding regions of the genome, most studies have focused on
interpreting genic mutations [1], even when whole-genome data
was generated [1–6]. As a consequence, it is unclear if and how non-
coding variants might contribute to cancer progression. To
comprehensively study functional consequences of somatic variants,
one needs cell cultures made from the tumor. First, though, one
needs to know how representative the cell culture is compared to the
original cancerous tissue. Here we characterize these differences
and use comparative and functional genomics methods to assess
how mutations are distributed within melanoma genomes.
We used a combination of data produced by the Illumina
GAIIx and HiSeq2000 platforms to generate over 5.4 billion
100 bp reads representing three different high-coverage genomes
(Figure 1A and S1) from the same 33 year old untreated male: two
genomes represent a cutaneous melanoma sample, one of a laser
capture microdissected metastatic tumor from the shoulder
(primary tumor is of unknown origin), and the other from a low-
passage cell-culture derived from that tumor. We also generated a
matched ‘‘normal’’ genome from a blood sample. Using our single
nucleotide genotype calling methodology [7], we were able to
make confident genotype calls at 92.9%, 84.5%, and 95.6% of the
tissue, cell culture, and normal genomes, respectively.
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Results/Discussion
Analysis of detected variants
To accurately and comprehensively identify novel somatic
single nucleotide variants (SSNVs) in the cell culture and tissue
genomes we developed a new computational algorithm, which was
validated and shown to have high sensitivity and specificity (see
Materials and Methods). Utilizing published algorithms [8–10], we
were also able to identify somatic copy number changes and
chromosomal rearrangements. Comparing the somatic alterations
identified in the tissue and cell culture genomes reveals their extent
of relatedness (Figure 1 and S2).
In total, we identified 105,460 SSNVs in the tissue and 122,837
in the cell culture that were not present in the patient’s non-tumor
DNA. This number of somatic mutations is substantially higher
than other published whole-genome cancer studies [1–6]. If we
examine genomic regions that have sufficient coverage to make a
reliable call in both samples (81.1% of the genome), 95.2% of the
sites are common (2.9% and 1.9% are unique to the tissue and cell
culture, respectively). The two melanoma samples are less
concordant at the level of copy number variations (CNVs) relative
to the normal genome (Figure 1C and 1D). In total, 118 Mb of the
cell culture has somatic CNVs whereas only 63 Mb of the tissue
does. In support of these results, we found that aCGH CNV calls
were highly concordant with our whole-genome sequencing-based
calls (Figure S3). One striking difference in the cell culture genome
is that it includes a near-complete loss of one copy of chromosome
14 (Figure S2 and S4). The additional CNVs in the cell culture
genome may result from the low-passage culturing process. This is
a known phenomenon that has been previously documented in
higher-passage hESC cell cultures [11] and a xenograft of a
primary tissue cancer sample [6]. As such, our CNV results are
consistent with other reports and extend these findings to lower-
passage tumor cell cultures. Because non-normal CNV regions can
influence SSNV calls, we recalculated concordance at non-CNV
regions. Focusing on these areas, there are 91,823 SSNVs in the
union of both samples, and 96.1% are shared (2.0% and 1.9% are
unique to the tissue and cell culture, respectively) (Figure 1B). The
SSNV mutational spectrum is reflective of UV damage, even for
cell culture and tissue-specific calls (Figure S5). We additionally
made somatic insertion and deletion (indel) calls (see Materials and
Methods), and found that after CNV filtering there are 269
somatic indels shared between the tissue and cell culture, while the
tissue has 127 unique indels and the cell culture has 160 (Figure
S6). This lower level of concordance, relative to SSNVs, between
calls is not surprising, as previous studies show that indel calling is
more difficult with short reads [12]. Together, these results provide
a high-resolution picture of the differences between a metastatic
tissue sample and the cell culture derived from it.
We next compared mutations from another melanoma whole-
genome study by applying our computational SSNV detection
method to sequence data from metastatic melanoma (colo-829)
and matched normal (colo-829BL) cell lines [1]. We identify more
SSNVs than originally reported, and the bulk of our calls are
concordant with those (Figure S7). Importantly, we identify 448 of
the 454 (98.7%) Sanger-validated and 40 of the 43 (93%)
COSMIC calls in the colo-829 genome. Variant calls that are
specific to our algorithm are enriched for the characteristic
melanoma UV mutational signature (Figure S8). We observe
100% concordance with Sanger sequencing-based cross-validation
of novel SSNV calls at 181 positions in the cell culture genome (see
Materials and Methods), which suggests that our SSNV detection
algorithm has a low false positive rate.
Additionally, we randomly selected 96 cell culture-specific and
96 tissue-specific SSNVs for PCR amplification and Sanger
sequencing. Of the successful PCR and Sanger sequencing
reactions, we observe 97.7% concordance and 98.7% concor-
dance at tissue-specific and cell culture-specific positions, respec-
tively. Together, these results suggest our SSNV detection
algorithm is both highly sensitive and specific.
Identification of commonly mutated genes in melanoma
Comparison of the colo-829 SSNVs to those from our
melanoma sample shows commonly mutated genes, some of
which are associated with melanoma pathogenesis (Figure S9). For
example, missense mutations (D261N and H533Y) were identified
in ADAM29, which encodes a member of the A Disintegrin And
Metalloproteinase (ADAMs) family which are membrane an-
chored glycoproteins with several biological functions encompass-
ing cell adhesion, cell fusion and signaling [1]. Importantly, we
recently reported that a systematic mutational analysis of all
members of the ADAM family of membrane-bound metallopro-
teases showed that ADAM29 is often mutated in melanoma [13].
Functional analyses have indicated that ADAM29 mutations affect
adhesion of melanoma cells to specific extracellular matrix
proteins, suggesting that mutated ADAM genes play a role in
melanoma tumorigenesis [13].
This study also identified a missense mutation (R175C) in
PTK2B, which encodes the non-receptor protein tyrosine kinase
PTK2B, also known as PYK2 or FAK2, a focal adhesion protein
that shares structural similarity with its paralog focal adhesion
kinase 1 (FAK1). PTK2B has been previously linked to metastasis
via RhoC-dependent activation of FAK1, MAPK, and Akt [14].
As we previously reported a high prevalence of somatic mutations
in PTK2B in metastatic melanoma [15], these studies suggest that
PTK2B may be a melanoma cancer gene and that further studies
are required to more fully characterize the functional role of its
mutations in melanoma. For additional genic annotations, we
include a supplementary file that outlines all coding mutations
discovered in this study (Table S1).
Nonrandom mutation accumulation across the genome
Because metastatic tumor formation involves successive itera-
tions of mutation, followed by selection and clonal expansion, the
resulting cell population has undergone an evolutionary process
commonly referred to as clonal evolution [16,17]. When
measuring the similarity of sequences across many species, the
genome has clear signatures of intense selective pressure [18–23].
Some regions reject mutations more than expected. To determine
Author Summary
Here we investigate the relationship between somatic
variants and non-coding regulatory regions. To do this, we
develop a new algorithm for identifying single nucleotide
somatic variants in whole-genome sequencing data and
apply it to a metastatic melanoma sample and a cell
culture derived from this sample. Our results show that the
two genomes are similar at the level of single nucleotide
changes and more variable at larger copy number
changes. We further observe that patterns of somatic
mutation accumulation in non-coding regulatory regions
suggests that the metastatic melanoma cells de-differen-
tiated into a more basal regulatory state. That is, by simply
looking at mutation accumulation across cell-type-specific
non-coding functional regions, one can clearly see
patterns that are indicative of cell state de-differentiation.
Results from genome-wide functional regulatory region
experimental mapping support this observation.
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if the selective forces operating on a metastatic cell over the span of
cancer development are similar to those operating across species
over millions of years, we compared somatic mutation accumu-
lation in melanoma to evolutionary constraint.
For this analysis, we combined the SSNVs from our tissue
sample with those we identified in the colo-829 cell line. This
resulted in 141,655 unique SSNVs, of which 99.3% are non-
coding. To determine if these mutations are uniformly distributed
throughout the genome, we first measured mutation accumulation
in functionally different regions identified by chromatin-based
chromosomal segmentations [24] (Figure 2A). Such segmentations
currently exist for nine different cell types (Figure S10), and we
chose NHEK cells as our primary focus since these appear most
similar to melanoma cells out of all nine cell types (see below). The
enrichment results are consistent when the samples are analyzed
independently (Figure S11). There is a clear anti-correlation with
evolutionary constraint (Figure 2B and S12). However, there is
also a strong anti-correlation with mutation accumulation and
coding regions (Figure 2C and S13), which is expected due to
transcription-coupled repair (TCR). Of note, the heterochromatin
low signal regions (state 13 in the chromosomal segmentations)
accumulate mutations roughly equal to random expectation
(Figure S14), indicating that they may be suitable targets for
estimating the background passenger somatic mutation rate (which
for this tumor we calculate as about 42 SSNVs per megabase).
The above results indicate that somatic mutations do not occur
uniformly across the genome. To eliminate the mutation
suppression bias related to TCR in known genic areas, we
specifically focused on regions of the genome less likely to be
transcribed— windows that do not overlap and are greater than
10 Kb from annotated genes or transcription start sites (TSSs). We
performed a multiple regression on mutation accumulation in bins
of these regions using evolutionary constraint, GC content, and
fraction of transcribed bases, which we obtained from a separate
melanoma RNA-seq study [25]. Adding the additional variables
removes the correlation with evolutionary constraint. Unsurpris-
Figure 1. Melanoma tissue and cell culture similarities. (A) The experimental design of our study. Concordance between the somatic calls in
the tissue (blue) and cell culture (yellow) for SSNVs (B), CNV amplifications (C), and CNV deletions (D). The two samples are highly concordant at the
SNV level, but more different at the CNV level.
doi:10.1371/journal.pgen.1002871.g001
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ingly, the fraction of non-coding bases transcribed (one of the
variables in the above-mentioned regression analysis) is almost
perfectly anti-correlated with enrichment for mutation accumula-
tion (Spearman’s R = 20.97789; P,2.2e-16). These results
suggest that TCR is a mechanism associated with preventing
mutation accumulation in non-coding regulatory elements.
Functional mutation signatures in non-coding regulatory
regions
We next sought to examine the distribution of somatic
mutations across experimentally-derived functional non-coding
regions. To do this, we compared our SSNV collection to broad
classes of active regulatory elements identified by the DNaseI
hypersensitive site (DHS) assay [26–30]. This experiment was
performed genome-wide on melanocytes—the precursor cell type
to melanoma—as part of the ENCODE Project Consortium [31].
We hierarchically partitioned melanocyte DHSs based on genic
landmarks and calculated somatic mutation enrichment
(Figure 3A). All DHS categories except for 39 UTRs are
significantly less enriched than random expectation (horizontal
line at 0) and compared to common SNPs from the 1000 genomes
consortium (grey points). 59 UTRs are the most depleted. These
results are consistent with the observed increase in mutation
accumulation along the length of genes (Figure S15) and are
reproducible when the samples are analyzed independently
(Figure S16). Despite their distant location from known tran-
scribed regions, intergenic TSS-distal DHSs are also significantly
depleted for accumulating mutations. To avoid confounding from
transcription-coupled repair (described above), we subsequently
focus on intergenic TSS-distal DHSs. We performed single linkage
clustering of DHSs from 29 different cell states (cell types and
conditions) identified by the ENCODE Project Consortium [31] to
identify sites that are cell-type-specific, present in a combination of
cell types, or ubiquitously present. Out of all cell-type-specific
DHSs, the most depleted for mutation accumulation are those
specific to melanocytes, aortic smooth muscle cells (ASMCs) and
H1 embryonic stem cells (ESCs). Ubiquitously present DHSs are
even more depleted. We next calculated the mutational load on all
melanocyte DHSs by measuring mutation accumulation when
these regulatory regions are active in all possible cellular contexts/
combinations. Unsurprisingly, mutation enrichment decreases as
the melanocyte DHS is active in more cell types (Figure 3C; yellow
line). As a control for this experiment we examined all
combinations of non-melanocyte DHSs and found a similar trend
Figure 2. Somatic mutation accumulation is non-random across the genome. (A) Somatic (blue) and common (gray) variants have different
levels of enrichment or depletion depending on which chromatin segmentation they occur in. Somatic mutation accumulation is highly anti-
correlated with evolutionary constraint (B) and coding fraction (C).
doi:10.1371/journal.pgen.1002871.g002
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(Figure 3C; blue line), although not as depleted as the melanocyte
DHSs. These results indicate that regulatory regions are prefer-
entially repaired in metastatic melanoma and that this occurs in a
cell-type specific manner.
To further understand the relationship between cell type
regulatory architecture and somatic mutation enrichment in
metastatic melanoma, we clustered all 29 cell types based on
their regulatory element signatures (Figure 3D). Note the
relationship between melanocytes and the other two cell types
where cell-type-specific DHS mutations are highly depleted
(ASMCs and ESCs). ASMCs are derived from the same
embryological layer—neural crest—as melanocytes, and ESCs
are an undifferentiated pluripotent cell type. Brain cell (medullo-
blastoma)-specific DHSs, which are also neural crest derived, show
significant depletion as well. The topology of the tree and the
significant depletion for somatic mutation accumulation in
regulatory regions specific to neural crest-derived and ESC cell
types suggests that the metastatic melanoma cell utilized these
regulatory programs. These results imply that the regulatory
architecture of the metastatic melanoma cell de-differentiated to a
more basal cellular program that is visible in the pattern of
mutations covering cell-type-specific regulatory regions. In support
of this hypothesis, a recent study found that human melanoma-
initiating cells express a neural crest stem cell marker [32].
To experimentally test the hypothesis of regulatory de-
differentiation, we performed genome-wide DNase-Seq to identify
DHSs in colo-829 and the cell culture sample sequenced in this
study. Generating trees using these two samples and DHSs from
the other cell types shows that the two melanoma samples are
closely related to each other and melanocytes (Figure 4A).
However, focusing on gene regulatory status by only considering
DHSs that overlap exonic regions shows a different tree topology
Figure 3. Non-coding Melanocyte DHSs are dis-enriched for accumulating melanoma somatic mutations. (A) Genic partitioning of
melanocyte DHSs such that every DHS occurs in a single category shows that most categories are depleted for mutation accumulation (TSS
P = Transcription Start Site Proximal [within 5 Kb]; TSS D = Transcription Start Site Distal [greater than 5 Kb]). Common SNPs are based on 1000
Genomes calls that have at least 5% minor allele frequency (MAF). (B) Intergenic TSS-distal cell-type-specific and ubiquitous DHSs show different
levels of enrichment or depletion. (C) Enrichment or depletion at cell-type combinations of intergenic TSS-distal melanocyte and non-melanocyte
DHSs. For these analyses, the set of regions representing any data point must have overlapped at least 10 somatic variants to be considered. The
horizontal black line at zero represents no enrichment. The GSC method was used to measure enrichment. Error bars represent one standard
deviation from the mean of the null distribution. (D) A hierarchical tree based on DHS Euclidean distance among 29 different cell states. Note the
positioning of melanocytes ‘‘Melano’’ relative to aortic smooth muscle cells ‘‘AosmcSerumfree’’ and human embryonic stem cells ‘‘H1hesc’’, which are
among the most depleted for somatic mutation accumulation (Figure 3B).
doi:10.1371/journal.pgen.1002871.g003
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(Figure 4B). Here, the melanomas are de-differentiated relative to
the melanocyte sample.
It is known that highly transcribed genes accumulate fewer
somatic mutations relative to more lowly transcribed genes [1].
Thus, the extent of TCR depends on the level of transcription.
Recent studies show that non-coding functional elements are
transcribed [33–36]. So, one would expect that somatic mutation
accumulation in these regions could be modulated by whether or
not, and to what extent, they are transcribed. To determine if
TCR might operate at melanoma-specific TSS-distal non-genic
regulatory regions, we calculated how many of these sites are
transcribed (Figure 4C). We found that melanoma-specific
regulatory regions are significantly more likely to be transcribed
(P,2.2 e216; Fisher’s Exact Test) relative to melanocyte-specific
regulatory regions. To further investigate this, we searched for a
hallmark signature of TCR—repair events biased to the
transcribed strand. Focusing on SSNVs overlapping the mela-
noma regulatory elements we identified that occur within introns
(so that we can orient mutations relative to the transcribed
strand), we observe a significant (P = 0.001605; exact binomial
test) strand bias (Figure 4D). These are the first results to our
knowledge that demonstrate the regulatory architecture at non-
coding regions in cancer genomes is de-differentiated and likely
shaped by TCR.
Here we have used whole-genome sequencing to identify the
somatic mutations in a metastatic melanoma tissue sample and a
low-passage cell culture derived from the same patient. We
speculate that the mutational signatures in the metastatic cell
indicate that regulatory architectures of the precursor cell it was
derived from and other basal cellular programs were utilized
Figure 4. The regulatory signature of metastatic melanoma. Genome-wide DNase-Seq identifies (DHS) regulatory elements in the cell culture
sample from our study and the colo-829 cell line. (A) Hierarchical clustering of all DHSs shows that the regulatory architecture of metastatic
melanoma cells (red) adopts that of a more derived melanocyte (blue). (B) Focusing on exon-overlapping DHSs to identify the open chromatin
landscape in gene regions shows that the metastatic melanoma cells are de-differentiated relative to melanocytes. Of the DHSs that occur in exonic
regions and are specific to the metastatic melanoma samples (and not present in any others), the important melanoma genes MITF, NEDD9, and DCC
are identified. (C) Melanoma transcription at melanoma-specific (dark blue) TSS-distal DHSs is significantly more frequent (P,2.2e216; Fisher’s Exact
Test) than at melanocyte-specific (light blue) TSS-distal DHSs. (D) Mutational bias in melanoma DHSs is asymmetric with respect to orientation relative
to the transcribed strand. The 12 possible mutations are collapsed into 6 such that the key mutation (A.C, for example; blue) and its complement
(T.G; yellow) version are represented with different colors. An asterisk (*) represents P,0.05 for a Binomial test, using a 50% expectation, on the
counts for a pair of key and complement mutations.
doi:10.1371/journal.pgen.1002871.g004
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during the path to metastasis—consistent with a tumorigenesis
model of embryonic program redeployment.
Materials and Methods
Tumor tissues
A pathology-confirmed metastatic melanoma tumor resection,
paired with a pheresis-collected peripheral blood mononuclear cells,
was collected from a 33 year old melanoma patient enrolled in IRB-
approved clinical trials at the Surgery Branch of the National Cancer
Institute. A portion of the fresh tumor was frozen and embedded in
Optimal Cutting Temperature (OCT) embedding medium. A
melanoma cell line was derived from mechanically dispersed tumor
cells, which were then cultured in RPMI 1640+10% FBS at 37uC in
5% CO2 for 9 passages. Genomic DNA was isolated using DNeasy
Blood & Tissue kit (Qiagen, Valencia, CA). Several quality controls
were performed one of which was the use of cytopathology, to
determine the percentage of melanoma antigen expressing cells. The
tissue culture line used in this study was evaluated by immunohis-
tochemistry to have at least 75% of cells express melanoma-specific
antigens. This threshold was set as it has been reported to give
sufficient purity to identify regions of homozygous deletion,
hemizygous deletion, copyneutral LOH, duplication and amplifica-
tion [37–39]. Genotyping of the samples was performed to verify
that they are derived from the same individual.
Melanoma tissue processing for Laser Capture
Microdissection (LCM)
H&E stained sections of fresh frozen melanoma tissues are
prepared for initial histologic assessment. Sections are examined
by a pathologist for the presence of tumor, estimation of tumor
content, presence of inflammation and necrosis. Tissues with less
than 70% tumor and/or significant areas of inflammation and
necrosis are subjected to LCM.
Laser Capture Microdissection (LCM)
Laser capture microdissection (LCM) was performed in the
Pathology Core Facility of MSKCC, New York, NY, using the
Veritas Microdissection System (Arcturus). The Veritas system
combines ultraviolet laser cutting and laser capture using an
infrared laser source. Fresh frozen melanoma tissues sectioned
between 8 and 10 mm were transferred to PEN membrane slides
(MDS Analytical Technologies) and sections were stained by using
a modified protocol described previously [40,41]. Briefly, sections
were stained with hematoxylin as follows: slides were immersed in
70% ethanol for about 10 min followed by sequential dips in
nuclease free water, Mayer’s hematoxylin solution for 30 sec,
nuclease free water, 75% ethanol, 95% ethanol and finally
dehydrated in absolute ethanol by 3 changes of 3 min each.
Multiple serial sections (10–20) of the tissue are used to
maximize cell yields. 5,000 to 10,000 cells were harvested in each
LCM cap and material from 5–10 caps was pooled together to
maximize yields.
DNA extraction
DNA was extracted using DNeasy Blood and Tissue kit (Qiagen)
following manufacturer’s instructions. DNA was eluted in 35 ul of
elution buffer. DNA measurements were made using ND-1000 UV-
Vis spectrophotometer from NanoDrop technologies.
Genome build statistics
We generated 5,409,104,173 100 base paired-end reads that
pass the Illumina chastity filter and contain 32 or more Q20
Sanger-scaled quality bases for this study, which were partitioned
among the genomes as follows: 1,042,502,044 for the cell culture,
1,588,246,159 for the tissue, and 2,778,355,970 for the normal.
Reads were aligned to the unmasked hg18 version of the human
genome using BWA [42] with default parameters. After removing
molecular duplicate read pairs (read pairs that map to the same
position on the reference sequence are likely an artifact of sample
preparation) using samtools [43] and considering only reads with a
mapping quality of Q30 or greater and bases with quality of Q20
or greater, we observe an average base coverage of 21.46, 29.66,
and 47.76 for the cell culture, tissue, and normal genomes,
respectively (Figure S1). Within coding regions, we were able to
make confident variant calls (see details below) at 64.3%, 85.2%,
and 88.9% of the positions in the cell culture, tissue, and normal
genomes, respectively. Comparing territory that is callable in the
cell culture and tissue results in 81.1% genome coverage.
Single nucleotide variants
For variant calling, only reads with mapping quality of Q30 or
greater and bases with quality of Q20 or greater were considered.
We used two related algorithms to make single-position genotype
calls in the normal and melanoma genomes. For all genomes, we
use a Bayesian genotype caller named Most Probable Genotype
(MPG) that has been described previously [44]. This genotype
caller produces accurate calls in regions that satisfy whole-genome
coverage and quality parameters as determined by a separate
study [7]. Namely, the MPG score must be equal or greater than
10 and the MPG score to base Q20 quality-coverage ratio must be
equal to or greater than 0.5. To independently verify MPG calls,
we compared genotypes to those called by the Infinium 1M quad
SNP-chip platform. The genotype concordance rate with the SNP-
chip for the normal genome is 99.937% at 99.3% of the positions,
excluding regions with hidden SNPs [45] and abnormal copy
number. A similar comparison performed on the cell culture
genome results in 99.939% concordance at 91.2% of the positions.
To better identify variant positions in the cell culture and tissue
genomes, we first developed a new algorithm similar to MPG,
called Most Probable Variant (MPV). An important distinction
between MPG and MPV is that the MPV score reflects the degree
of confidence that a sample has a genotype different from the
reference genome, whereas the MPG score reflects the degree of
confidence in the genotype call itself. MPV is a new option (–
score_variant) in the MPG program and the executable source
code is freely available for download from the following URL:
http://research.nhgri.nih.gov/software/bam2mpg/. We opti-
mized calling parameters for MPV by downloading and analyzing
genome-wide tumor and normal data that was previously
published for the colo-829 melanoma and colo-829BL normal
cell lines [1]. Using MPV with optimized parameters (MPV score
must be greater than or equal to 10 with no coverage ratio criteria
similar to the MPG parameters) on the cell culture genome allows
us to identify more variant positions without dramatically
sacrificing accuracy (Table S2). Comparing MPV calls for the
cell culture genome to the SNP-chip results in 99.79%
concordance at 96.28% of the variant positions.
To identify novel somatic single nucleotide variant (SSNV)
positions we compared the MPV-called genotype in either
melanoma genome to the MPG-called genotype in the normal
genome and then subtracted out any variants that are present in
dbSNP129 or within ten bases of an indel identified by the MPV
algorithm. Loss of heterozygosity (LOH) variants were ignored
since there is no novel somatically-acquired allele.
Running our analysis pipeline on our own samples resulted in
122,837 SSNVs in the cell culture genome and 105,460 in the
Signatures of De-Differentiation in Tumor Genomes
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tissue genome. It is important to note that these two numbers are
not comparable because they are not normalized across the
common callable territory in the cell culture and tissue genomes.
Once we account for this, the somatic variant counts drop to
97,532 for the cell culture and 98,548 for the tissue.
We validated novel SSNVs by PCR amplifying the regions in
the cell culture and normal genomes and then Sanger
sequencing the products. Of 192 randomly chosen positions
(96 in coding regions, and 96 in non-coding regions), we were
able to successfully PCR amplify and Sanger sequence 181 in
both genomes. Of these, we observed evidence for somatic
variants concordant with the whole-genome data at 100% of the
positions.
For further validations we randomly selected 96 cell culture-
specific and 96 tissue-specific SSNVs for PCR amplification and
Sanger sequencing. Of the 78 successful PCR and Sanger
sequencing reactions for the cell culture set, 75 (96%) had
genotype calls concordant with the whole-genome sequencing call.
For the tissue set, 43/73 (59%) were concordant. This result
allowed us to focus on the 30 positions where the tissue-specific
whole-genome calls were not concordant with the PCR and
Sanger calls. We found that by implementing three simple filters,
we eliminated 29 of 30 discordant positions and 0 of 43
concordant positions, so that the concordance rate is 43/44
(97.7%). The filters we implemented are:
1. Normal lookup filter to check for somatic variant alleles in the
normal genome, as previously described [5].
2. Indel filter to remove somatic variant calls within 10 bases of an
indel call made using reads with a mapping quality of 1 or
greater and a MPV score of 10 or greater in the tumor genome.
3. Strand bias filter to remove calls where the somatic allele is
present exclusively in reads mapping to one strand and not the
other.
These filters removed 2 of 3 discordant cell culture-specific calls
and 0 of 75 concordant calls, so that the concordance rate is 75/76
(98.7%).
We additionally looked at the mutation spectrum for all the
common, tissue-specific, and cell culture-specific SSNVs (Figure
S5). All three mutation spectrums are enriched for the known
G.A/C.T UV signature. Together, these results suggest that
our method is highly specific.
Cellular heterogeneity
To estimate the extent of normal cell contamination in the cell
culture and tissue samples, we calculated the fraction of reads with
mapping quality of at least 30 supporting the acquired somatic
allele at heterozygous positions and compared this to what would
be expected in a completely homogenous cellular population with
no normal cells. Our analyses show that the cell culture has no
normal contamination, while the tissue sample contains about
42% normal cells (Figure S17). Other groups have used similar
methods to estimate tumor sample purity [46].
Copy number variants
We first estimate copy number in non-overlapping 5 Kb tiles in
the normal genome using the copySeq algorithm [8]. We only
consider tiles with 80% uniquely mappable k-mers (which is 94%
of the tiles) to ensure accurate copy number estimation. To detect
amplifications and deletions in the cancer genomes we use the
CNV-seq algorithm [9], which compares the cancer to normal
genome, with the following parameters:
{p-value 0:0001 {bigger-window 10{global-normalization
Somatic copy number alterations (SCNAs) are then defined over
the 5 kb tiles called in the normal genome using CNV-seq results
and copy number is adjusted based on the level of normal genome
contamination, as described above. Adjacent amplified or deleted
5 kb windows are merged and only regions where two or more
windows are affected are retained. To conservatively identify tissue
or cell culture-specific CNVs, we filtered the CNV-seq calls in one
sample by looking at the corresponding log2 ratio in the other
sample. Any CNV-called regions in one sample with a CNV log2
ratio, = 20.1 or . = 0.1 in the other sample were considered
CNVs even if they were not called by the CNV-seq algorithm.
Thus, these regions are not considered sample-specific, which
result in a conservative set of CNV calls.
Somatic insertions and deletions
We made somatic insertion and deletion calls by extending our
MPV and MPG scoring methodology (see Single nucleotide
variants section above) to indel calls. We first select all possible
non-reference indel calls, irrespective of score threshold, across all
three genomes using MPG on the normal genome and MPV on
the tumor genomes. After merging all possible calls, we then look
at each genome independently and determine how well the reads
support the indel call using MPG on the normal genome and
MPV on the tumor genome, both with thresholds of 10. To find
somatic indels we keep non-reference tumor calls that do not
match the normal call at that same position. Because CNVs can
bias indel calls, we subsequently filter by retaining regions where
the CNV log2 ratio .20.1 and ,0.1 such that a conservative set
of indels outside CNV regions are compared. The final indel
results are summarized in Figure S6.
Array comparative genome hybridization (aCGH)
We used an Agilent 180K aCGH array to look for CNVs in the
tissue sample. For gain/loss calls, we used the default Nexus 6.0
settings for Agilent 180K catalog arrays for mosaic tissue samples,
and adjusted the minimum probe bin size to 10 instead of the
default 3 for segmentation
Chromosomal rearrangements
We used the BreakDancer algorithm [10] to detect chromo-
somal rearrangements. In order to detect somatic events we
require a score of 90 or greater in the cancer genome, which is
consistent with parameters reported in a previous study [6] and no
evidence in the normal genome. We further filter the results in two
ways. First, by removing any somatic events that occur in any of
ten normal genomes from an ongoing internal study (data not
shown). Second, by requiring that the 2 kb region immediately
surrounding each putative breakpoint is greater than 99%
mappable according to the CRG 100mer alignability track
available at the UCSC genome browser.
Mutation accumulation enrichment
We used the Genome Structure Correction (GSC) method [47]
to calculate enrichment statistics for SSNVs relative to other
genomic features. All results are based on 10000 samplings and
reported as the log2 fraction of observed base overlaps divided by
the mean of the null overlaps. Error bars represent +/2 one
standard deviation from the mean of the null distribution. We
calculate enrichment or depletion only in situations where ten or
more SSNVs overlap a particular set of genomic features. If there
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are fewer overlaps, we consider the calculation unreliable and
therefore ignore those comparisons. Common SNP control data
sets were constructed using 1000 Genomes calls [48] at positions
that have a minimum of 5% minor allele frequency (MAF) and are
concordantly called across four different centers. Similar results
are observed when using 20% MAF SNPs (data not shown).
Chromatin segmentations
Chromatin segmentation data for nine different cell types was
obtained from Ernst et al. [24]. We ignored states 14 and 15,
which correspond to repetitive regions of the genome. Variant
calls are generally filtered out of these areas by the 1000 Genomes
Consortium because they result in high false positives rates. These
two states combined occupy 0.27% of the genome on average over
the nine different cell types, so ignoring them will have little effect
on our analyses.
Hierarchical gene-landmark partitioning
We divided genomic features into hierarchical and mutually
exclusive categories based on the following hierarchical sequence
of genic landmarks: coding regions, 59 UTR’s, 39 UTR’s, introns,
intergenic transcription start site (TSS)-proximal (within 5,000 bp
of a TSS), and intergenic TSS-distal (greater than 5,000 bp from a
TSS). All genic landmarks are based on the GENCODE
annotation [49] in hg18 and can be downloaded from the UCSC
Genome Browser [genome.ucsc.edu].
Non-genic tiles
We masked out all regions of the genome overlapping with, or
within 10,000 bp, of any part of a gene or TSS. For the remaining
parts of the genome, we created 50,000 bp non-overlapping tiles and
calculated the number of bases that overlap evolutionarily constrained
regions. Constrained regions are based on the GERP method [20]
and the Enredo, Pecan, Ortheus (EPO) alignments [50,51] and are
available at the Ensembl browser [www.ensembl.org]. We discarded
tiles with no constrained region overlap and sorted the remaining tiles
by the fraction of constrained base overlaps. Using this sorted list, we
created ten equal-sized bins and calculated mutation accumulation
enrichment (see above) for the tiles within each bin.
DNase I Hypersensitive Site (DHS) data sets and analysis
We used post-embargo ENCODE Consortium DHS data sets for
the following 29 cell lines: AosmcSerumfree, Chorion, Fibrobl,
Fibrop, Gm12878, Gm12891, Gm12892, Gm18507, Gm19238,
Gm19239, Gm19240, H1hesc, H9es, Helas3Ifna4h, Helas3, Hepg2,
Hsmm, Hsmmt, Huvec, K562, Lhsr, LhsrAndro, Mcf7, Medullo,
Melano, Myometr, Nhek, Panislets, Progfib. Information about the
cell lines and DHS experiments can be found at the UCSC ENCODE
Open Chromatin, Duke/UNC/UT Track Settings Page: http://
genome.ucsc.edu/cgi-bin/hgTrackUi?g = wgEncodeChromatinMap.
Enrichment statistic measurements and gene-landmark parti-
tioning for DHS regions were performed as described above.
Single-linkage clustering was performed on all DHSs across the 29
cell lines to determine regions that are active in single, multiple,
and all cell types. The DHS signature tree was constructed by first
creating a binary vector for each cell type that classifies a region as
either on (1) or off (0). Then, Euclidean distance was used as a
metric to hierarchically cluster the binary vectors. The resulting
trees were manipulated with the Dendroscope program [52] to re-
root using the GM cell types as an out group. Figure 4 reports the
result of this analysis on all DHSs, but we observe the same tree
topology when only non-genic TSS-distal DHSs are considered
(data not shown).
Experimental DHS identification in melanoma samples
DNase-seq libraries we generated as previously described
[29,30] and sequenced via Illumina’s GAII sequencer. After
alignment to the human reference sequence, we used F-seq [53] to
identify DHS peaks. These peaks were compared to DHS regions
identified in the same manner from other cell types.
Transcription at DHSs
We used transcribed regions from ten melanoma samples as
defined by Berger et al. [25]. A DHS element is considered
transcribed if any high mapping quality (mapQ. = 30) RNA-seq
read from any of the ten melanoma samples overlaps the DHS.
Supporting Information
Figure S1 Reference genome coverage for all three samples
using reads with a mapping quality of Q30 or greater and bases
with a base quality of Q20 or greater.
(TIF)
Figure S2 Somatic alterations in the tissue (A) and cell culture
(B) genomes. Whole-genome SSNV, SCNA, and translocation
results are presented for each sample. Blue bars represent the
number of SSNVs per 10 Mb. Interior to the blue bars, blue lines on
a gray background represent SCNAs from copy one to five. Inside
the circle, red and gray lines represent interchromosomal and
intrachromosomal translocations, respectively.
(TIF)
Figure S3 Somatic copy number alterations (SCNAs) called
using the whole-genome data have a high degree of concordance
with SCNAs called using aCGH data.
(TIF)
Figure S4 Copy number variation (CNV) differences in the cell
culture and tissue genomes relative to the normal genome. In some
instances, tissue CNV regions appear to nucleate larger CNV
events in the cell culture.
(TIF)
Figure S5 The mutational spectrum for all common, cell
culture-specific, and tissue-specific SSNVs.
(TIF)
Figure S6 Somatic indel calls in the tissue and cell culture
samples. (A) After CNV filtering there are 269 shared somatic
indel events, while the tissue (blue) has 127 unique events and the
cell culture (yellow) has 160 unique events. (B) Somatic indel size
counts show that smaller indels (around size +1 or 21) are more
common than larger events.
(TIF)
Figure S7 A comparison of SSNVs called on the colo-829 using
the method presented here and the method originally described by
Pleasance et al. [1].
(TIF)
Figure S8 The mutational spectrum for SSNVs called on the
colo-829 genome.
(TIF)
Figure S9 Shared genic mutations among the samples. Numbers
indicate the count of genes with a nonsynonymous or stop
mutation. These numbers reflect variants at all callable positions
per genome, not normalized across commonly callable territory.
Genes with star superscripts are implicated in melanoma
pathogenesis by other studies.
(TIF)
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Figure S10 Variant enrichment in chromatin segmentations
across nine different cell types.
(TIF)
Figure S11 Variant enrichment in chromatin segmentations
across nine different cell types using samples analyzed indepen-
dently.
(TIF)
Figure S12 Somatic mutation enrichment compared to fraction
of evolutionarily constrained bases in chromatin segmentations
across nine different cell types. R values represent Spearman’s
correlation.
(TIF)
Figure S13 Somatic mutation enrichment compared to fraction
of coding bases in chromatin segmentations across nine different
cell types. R values represent Spearman’s correlation.
(TIF)
Figure S14 Regions that are heterochromatin low signal zones
(state 13) accumulate somatic mutations at a rate similar to
random expectation.
(TIF)
Figure S15 Mutation accumulation increases with distance
along known transcripts. Each point represents a 5 Kb bin.
(TIF)
Figure S16 Genic partitioning of melanocyte DHSs such that
every DHS occurs in a single category shows that most categories
are depleted for mutation accumulation (TSS P = Transcription
Start Site Proximal [within 5 Kb]; TSS D = Transcription Start
Site Distal [greater than 5 Kb]). Common SNPs are based on
1000 Genomes calls that have at least 5% minor allele frequency
(MAF). In addition to a union analysis, each sample is also
analyzed independently in this plot.
(TIF)
Figure S17 Normal cell contamination levels are different in the
cell culture (A) and tissue (B) samples. We measured the fraction of
MapQ30 reads that support the somatic allele at heterozygous
positions and compared this to a binomial distribution fitted to the
observed read counts. As expected, the cell culture has no normal
cell contamination, but the tissue sample does. Based on location
of the observed tissue peak at 0.29 relative to the expected peak at
0.5, we estimate the tissue sample contains approximately 42%
((0.5–0.29)*2*100) normal cells.
(TIF)
Table S1 Coordinates, gene names, and amino acid changes
(where applicable) for all genic mutations in the cell culture and
tissue sample.
(XLS)
Table S2 We compared the genotype calls made on the whole
genome data using the MPG and MPV algorithms to SNP-chip
calls made on the same samples. Three sets of positions were
considered: 1) all SNP-chip positions, 2) hidden SNPs (positions on
the SNP-chip where a nearby SNP could affect probe hybridiza-
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